Home › Funds › Arrowstreet Capital › BSX

Arrowstreet Capital position in BSX

BOSTON SCIENTIFIC CORP · Health Care

Arrowstreet Capital reported holding 28,466,177 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$1.24B, representing 0.53% of its reported portfolio and ranking #28 among its reported holdings. Arrowstreet Capital has disclosed BSX holdings in 37 of the last 43 reported quarters, going back to Q1 2016.

Latest position (Q3 2026)28.47M sh
Reported value held$1.24B
Portfolio Weight0.53%
First reportedQ1 2016
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Arrowstreet Capital's BSX position evolved

Arrowstreet Capital first disclosed a stake in BSX in Q1 2016 at 247,700 shares (US$4.7M). The position peaked in Q3 2026 at 28,466,177 shares, worth US$1.24B. Across 37 filings, Arrowstreet Capital increased the stake 22 time(s), trimmed it 11 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 28,466,177 shares valued at US$1.24B — an increase of 5,172,264 shares quarter over quarter.. Notable position changes include a 372% increase in Q4 2017, a 2692% increase in Q4 2020, a 2849% increase in Q3 2021 (shares fell 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2016 247.70K $4.66M New
Q2 2016 624.00K $14.58M Add
Q3 2016 2.57M $61.15M Add
Q4 2016 4.40M $95.27M Add
Q1 2017 4.78M $118.86M Add
Q2 2017 2.01M $55.75M Reduce
Q3 2017 1.52M $44.23M Reduce
Q4 2017 7.15M $177.25M Add
Q1 2018 878.17K $23.99M Reduce
Q4 2018 10.60K $375.00K New
Q1 2019 6.30K $242.00K Reduce
Q1 2020 2.01M $65.70M New
Q2 2020 83.02K $2.92M Reduce
Q3 2020 8.70K $332.00K Reduce
Q4 2020 242.90K $8.73M Add
Q2 2021 29.90K $1.28M New
Q3 2021 881.72K $38.26M Add
Q4 2021 3.27M $139.04M Add
Q1 2022 5.43M $240.53M Add
Q2 2022 7.54M $281.00M Add
Q3 2022 7.85M $303.93M Add
Q4 2022 8.48M $392.42M Add
Q1 2023 8.53M $426.88M Add
Q2 2023 8.89M $481.12M Add
Q3 2023 7.64M $403.23M Reduce
Q4 2023 6.05M $349.62M Reduce
Q1 2024 4.90M $335.73M Reduce
Q2 2024 4.81M $370.76M Reduce
Q3 2024 5.11M $427.80M Add
Q4 2024 5.59M $499.47M Add
Q1 2025 6.75M $681.41M Add
Q2 2025 6.53M $701.38M Reduce
Q3 2025 8.37M $816.91M Add
Q4 2025 11.04M $1.05B Add
Q1 2026 13.89M $871.70M Add
Q2 2026 23.29M $994.18M Add
Q3 2026 28.47M $1.24B Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 17 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has Arrowstreet Capital held BSX?

Arrowstreet Capital has disclosed BSX holdings in 37 of the last 43 reported quarters, going back to Q1 2016.

What is Arrowstreet Capital's current position in BSX?

As of Q3 2026, Arrowstreet Capital holds 28.47M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $1.24B, representing 0.53% of its reported portfolio and ranking #28.

Has Arrowstreet Capital been buying or selling BSX?

In the latest 13F filing (Q3 2026), Arrowstreet Capital increased its position in BSX. The position peaked in Q3 2026 at 28.47M shares.

Which other funds hold BSX?

Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, D. E. Shaw & Co, among 17 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.